Literature DB >> 9765404

Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

S Pepperl1, G Benninger-Döring, S Modrow, H Wolf, W Jilg.   

Abstract

We analyzed the immediate-early transactivator Rta of Epstein-Barr virus (EBV) for its role as a target for specific cytotoxic T lymphocytes (CTL). Panels of overlapping peptides covering the entire amino acid sequence of Rta were synthesized and used to induce and analyze specific CTL responses in EBV-positive donors. Using peptide-pulsed target cells, we found nine different CTL epitopes that are distributed over the entire protein sequence. One epitope restricted by HLA-A24 could be mapped to the decameric sequence DYCNVLNKEF between amino acid positions 28 and 37 of the Rta protein. A second epitope could be assigned to the same region of Rta (residues 25 to 39) and was shown to be restricted by HLA-B18. Another, minimal epitope could be mapped to the nonameric sequence ATIGTAMYK between amino acid positions 134 and 142; this peptide was restricted by HLA-A11. Another four epitopes were proven to be restricted by HLA-A2, -A3, -B61, and -Cw4 and were located between Rta residues 225 and 239, 145 and 159, 529 and 543, and 393 and 407, respectively. For two other epitopes, only the location within the Rta protein is known so far (residues 121 to 135 and 441 to 455); their exact HLA restriction patterns have not yet been identified. Using target cells infected with recombinant vaccinia virus containing the gene for Rta, we showed that six of eight Rta-specific CTL lines recognized the corresponding peptides also after endogenous processing. These data suggest that Rta comprises an important target for EBV-specific cellular cytotoxicity. Together with recent findings of other immediate-early and early proteins also acting as CTL targets, they reveal the role of proteins of the lytic cycle in the immune recognition of EBV-infected cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9765404      PMCID: PMC110276     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The specificity of recognition of a cytotoxic T lymphocyte epitope.

Authors:  S R Burrows; S J Rodda; A Suhrbier; H M Geysen; D J Moss
Journal:  Eur J Immunol       Date:  1992-01       Impact factor: 5.532

2.  An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Authors:  S R Burrows; I S Misko; T B Sculley; C Schmidt; D J Moss
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

3.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules.

Authors:  K Falk; O Rötzschke; S Stevanović; G Jung; H G Rammensee
Journal:  Nature       Date:  1991-05-23       Impact factor: 49.962

4.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

5.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  The role of Epstein-Barr virus in lymphomas of HIV-carriers.

Authors:  I Ernberg; E Altiok
Journal:  APMIS Suppl       Date:  1989

Review 7.  Severe chronic active Epstein-Barr virus infection syndrome.

Authors:  M Okano; S Matsumoto; T Osato; Y Sakiyama; G M Thiele; D T Purtilo
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

8.  Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes.

Authors:  S Pothen; J R Richert; G R Pearson
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

9.  An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).

Authors:  S R Burrows; T B Sculley; I S Misko; C Schmidt; D J Moss
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA.

Authors:  J A McCutcheon; J Gumperz; K D Smith; C T Lutz; P Parham
Journal:  J Exp Med       Date:  1995-06-01       Impact factor: 14.307

View more
  20 in total

1.  Identification of human herpesvirus 8-specific cytotoxic T-cell responses.

Authors:  M Osman; T Kubo; J Gill; F Neipel; M Becker; G Smith; R Weiss; B Gazzard; C Boshoff; F Gotch
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  The immunology of Epstein-Barr virus infection.

Authors:  D J Moss; S R Burrows; S L Silins; I Misko; R Khanna
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

3.  Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Authors:  Barbara Adler; Eveline Schaadt; Bettina Kempkes; Ursula Zimber-Strobl; Barbara Baier; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

4.  Nucleocytoplasmic shuttling and CRM1-dependent MHC class I peptide presentation of human cytomegalovirus pp65.

Authors:  Nadine Frankenberg; Peter Lischka; Sandra Pepperl-Klindworth; Thomas Stamminger; Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2012-09-11       Impact factor: 3.402

5.  Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression.

Authors:  S Pepperl; J Münster; M Mach; J R Harris; B Plachter
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.

Authors:  Sinéad Keating; Stuart Prince; Matthew Jones; Martin Rowe
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Prevalence of periodontitis in individuals with human leukocyte antigens (HLA) A9, B15, A2, and B5.

Authors:  Jamal M Stein; Helmut K G Machulla; James Deschner; Stefan Fickl; Yvonne Jockel-Schneider; Miriam Tamm; Susanne Schulz; Stefan Reichert
Journal:  Clin Oral Investig       Date:  2015-08-26       Impact factor: 3.573

8.  Kaposi's sarcoma: a computational approach through protein-protein interaction and gene regulatory networks analysis.

Authors:  Aubhishek Zaman; Md Habibur Rahaman; Samsad Razzaque
Journal:  Virus Genes       Date:  2012-12-25       Impact factor: 2.332

9.  Identification of a tumor-specific allo-HLA-restricted γδTCR.

Authors:  G J J Kierkels; W Scheper; A D Meringa; I Johanna; D X Beringer; A Janssen; M Schiffler; T Aarts-Riemens; L Kramer; T Straetemans; S Heijhuurs; J H W Leusen; E San José; K Fuchs; M Griffioen; J H Falkenburg; L Bongiovanni; A de Bruin; D Vargas-Diaz; M Altelaar; A J R Heck; L D Shultz; F Ishikawa; M I Nishimura; Z Sebestyén; J Kuball
Journal:  Blood Adv       Date:  2019-10-08

10.  CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Authors:  Rachel J M Abbott; Laura L Quinn; Alison M Leese; Harry M Scholes; Annette Pachnio; Alan B Rickinson
Journal:  J Immunol       Date:  2013-10-21       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.